Review papers with raw data transparency

Visual-first review: Ragge et al., "SOX2 Anophthalmia Syndrome" (DOI:10.1002/ajmg.a.30642)

Critical appraisal (evidence-weighted)

1. Strengths
   • Clear molecular confirmation with parental testing establishes mostly de novo origin of pathogenic alleles, strengthening causality (SOX2 variants absent in 200 screened controls) De novo status and control screening
   • Detailed phenotyping (ophthalmic exam, orbital surgery history, MRI brain) allows credible genotype–phenotype mapping within a rare disorder where cohorts are small Phenotyping detail
2. Limitations & potential biases
   • Small sample size (n=9 carriers) — inevitable for rare disorders but limits generality and quantitative penetrance estimates; authors acknowledge need for larger series Sample size limitation
   • Ascertainment bias: cohorts enriched for severe MAC (referral to specialist units and selection for screening) inflates frequency of extraocular anomalies and bilateral severe forms relative to population-based series — caution when extrapolating prevalence estimates Ascertainment context
   • Functional mechanisms remain inferential: authors argue haploinsufficiency (and truncated proteins possibly exerting dominant-negative effects) but provide no biochemical functional assays for the new variants (e.g., p.L97P) — subsequent work (beyond this paper) is needed for mechanistic validation Mechanistic inference and limits
3. Interpretation robustness
   • Clinical consistency (ocular + mesial temporal brain +/- seizures, motor planning abnormalities, male genital anomalies) across unrelated de novo cases strongly supports a syndromic effect of SOX2 dosage in human development; negative evidence from Sox2+/- mice (apparently mild) highlights human-specific sensitivity or developmental timing differences Human vs mouse sensitivity

Where data are incomplete or risky to over-interpret

• No systematic population prevalence or penetrance estimates — the authors present case frequencies from clinic cohorts but these cannot be extrapolated to population incidence without bias correction No population prevalence
• Functional impact of truncating alleles that escape nonsense-mediated decay (single-exon gene) is ambiguous — predicted truncated peptides could be produced and act dominant-negatively; functional assays (DNA-binding, transcriptional activation/repression, nuclear localization) are required to resolve mechanism for each allele.
• Potential under-ascertainment of non-ocular SOX2 effects in carriers with milder eye defects: later studies (e.g., larger SOX2 screens) show broader phenotypic spectrum, including AEG features; clinical recommendations should reflect spectrum (paper was careful, but clinicians must note variable expressivity) Subsequent phenotype expansion

Practical recommendations (clinically actionable)

1. Offer SOX2 sequencing and copy-number testing (deletion/duplication analysis) as first-line in infants with bilateral severe anophthalmia or bilateral MAC — the paper provides direct evidence supporting high diagnostic yield in such cases Testing recommendation
2. Baseline neurodevelopmental surveillance, seizure screening, and consideration of MRI focused on mesial temporal structures in mutation carriers — the paper documents hippocampal/parahippocampal malformations in multiple cases and seizure association MRI and seizure guidance
3. For male infants: endocrine/genital assessment (micropenis/cryptorchidism) and endocrine follow-up given observed genital tract anomalies and possible pituitary involvement in some cases Genital and pituitary assessment

What would change the conclusions — falsifiability checklist

• If large population-based screens found frequent benign SOX2 variants with identical molecular signatures and no phenotype, the causal link would be weakened (but current evidence is de novo and absent from controls, arguing against this).
• If robust functional assays showed truncated SOX2 peptides rescue function or produce no loss-of-function effect, the haploinsufficiency model would need revision — functional data are the next crucial step.

Suggested next experiments (concise, testable)

1. In vitro functional panel for new variants (DNA-binding EMSA, transactivation reporter assays, nuclear localization, protein stability) to test haploinsufficiency vs dominant-negative mechanisms for truncating and p.L97P alleles.
2. Induced pluripotent stem cell (iPSC)–derived optic cup organoids and hippocampal neurons from affected patients (or engineered isogenic alleles) to model tissue-specific consequences of SOX2 dosage reduction and capture human-specific phenotypes that mouse heterozygotes miss.